| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England Journal of Medicine 369 (18), 1691-1703, 2013 | 6621 | 2013 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1158 | 2016 |
| Novel agents on the horizon for cancer therapy WW Ma, AA Adjei CA: a cancer journal for clinicians 59 (2), 111-137, 2009 | 442 | 2009 |
| Pancreatic adenocarcinoma, version 2.2014 MA Tempero, MP Malafa, SW Behrman, AB Benson, ES Casper, ... Journal of the National Comprehensive Cancer Network 12 (8), 1083-1093, 2014 | 406 | 2014 |
| Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines MA Tempero, JP Arnoletti, SW Behrman, E Ben-Josef, AB Benson, ... Journal of the National Comprehensive Cancer Network 10 (6), 703-713, 2012 | 338 | 2012 |
| Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas … DD Von Hoff, TJ Ervin, FP Arena, EG Chiorean, JR Infante, MJ Moore, ... Journal of Clinical Oncology 31 (4_suppl), LBA148-LBA148, 2013 | 183 | 2013 |
| A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response JWL Eng, KM Kokolus, CB Reed, BL Hylander, WW Ma, EA Repasky Cancer Immunology, Immunotherapy 63, 1115-1128, 2014 | 176 | 2014 |
| Immunotherapy for colorectal cancer PM Boland, WW Ma Cancers 9 (5), 50, 2017 | 159 | 2017 |
| Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ... JAMA oncology 6 (12), e204930-e204930, 2020 | 156 | 2020 |
| Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation JWL Eng, CB Reed, KM Kokolus, R Pitoniak, A Utley, MJ Bucsek, WW Ma, ... Nature communications 6 (1), 6426, 2015 | 146 | 2015 |
| [18F] fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy WW Ma, H Jacene, D Song, F Vilardell, WA Messersmith, D Laheru, ... Journal of clinical oncology 27 (16), 2697, 2009 | 136 | 2009 |
| Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity WW Ma, MW Saif, BF El‐Rayes, MG Fakih, TH Cartwright, JA Posey, ... Cancer 123 (2), 345-356, 2017 | 128 | 2017 |
| A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic … BH O'neil, AJ Scott, WW Ma, SJ Cohen, DL Aisner, AR Menter, MA Tejani, ... Annals of Oncology 26 (9), 1923-1929, 2015 | 126 | 2015 |
| Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer I Garrido-Laguna, AC Tan, M Uson, M Angenendt, WW Ma, MC Villaroel, ... British journal of cancer 103 (5), 649-655, 2010 | 87 | 2010 |
| Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer EG Chiorean, DD Von Hoff, J Tabernero, R El-Maraghi, WW Ma, M Reni, ... British journal of cancer 115 (2), 188-194, 2016 | 80 | 2016 |
| Contemporary management of localized resectable pancreatic cancer A Kommalapati, SH Tella, G Goyal, WW Ma, A Mahipal Cancers 10 (1), 24, 2018 | 78 | 2018 |
| Pharmacodynamic-guided modified continuous reassessment method–based, dose-finding study of rapamycin in adult patients with solid tumors A Jimeno, MA Rudek, P Kulesza, WW Ma, J Wheelhouse, A Howard, ... Journal of clinical oncology 26 (25), 4172, 2008 | 77 | 2008 |
| A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors LS Rosen, P LoRusso, WW Ma, JW Goldman, A Weise, AD Colevas, ... Investigational new drugs 34, 604-613, 2016 | 74 | 2016 |
| The winning formulation: the development of paclitaxel in pancreatic cancer WW Ma, M Hidalgo Clinical Cancer Research 19 (20), 5572-5579, 2013 | 72 | 2013 |
| A multicenter phase II study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer RV Iyer, VK Pokuri, A Groman, WW Ma, U Malhotra, DM Iancu, C Grande, ... American Journal of Clinical Oncology 41 (7), 649-655, 2018 | 70 | 2018 |
Manuel HidalgoWeill Cornell MedicineVerified email at med.cornell.edu
